Exploring a Translational Biomarker Framework for Cell & Gene Therapies
- Showcasing the rationale behind selecting biomarkers to answer modality‑specific questions for cell and gene therapies
- Highlighting how PDX models are used to back‑translate clinical observations
- Demonstrating how validated assay outputs directly inform clinical strategy, strengthening patient‑selection, response‑stratification and biomarker frameworks for early‑phase trials